冠状病毒基因组特征及感染特点比较<sup>*</sup>

doi:10.13523/j.cb.2005012

中国生物工程杂志

2020, Vol. 40

Issue (11): 56-66 DOI: 10.13523/j.cb.2005012

综述

冠状病毒基因组特征及感染特点比较^*

程子昭¹,陈楚楚¹,应磊²,李校堃¹,黄志锋^1**(

)

1 温州医科大学药学院温州 325035
2 温州医科大学基础医学院温州 325035

Comparison of Genomic and Infection Characteristics of Coronavirus

CHENG Zi-zhao¹,CHEN Chu-chu¹,YING Lei²,LI Xiao-kun¹,HUANG Zhi-feng^1**(

)

1 School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China
2 School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China

全文: PDF(5578 KB) HTML

摘要：

冠状病毒是一种可以引起人呼吸系统、消化系统等疾病的病原体。目前,对冠状病毒的了解还不够深入,尚不清楚新型冠状病毒(SARS-CoV-2)与其他人冠状病毒在生物学特点和感染机制、流行病学与临床特点等方面的异同,通过概括包括SARS-CoV-2在内的几种冠状病毒的特点,并分析SARS-CoV-2在特殊人群中的易感性及预后等特点,为临床研究和鉴别诊断提供参考和依据。

关键词： 冠状病毒; 基因组结构; 感染机制; 流行病学; 临床特点

Abstract:

Coronavirus is a kind of pathogen that can cause respiratory and digestive diseases. At present, the understanding of coronavirus is not deep enough, and the similarities and differences between SARS-CoV-2 and other human coronaviruses in biological characteristics, infection mechanism, epidemiology and clinical characteristics are not clear. By summarizing the characteristics of several coronaviruses including SARS-CoV-2, and analyzes the susceptibility and prognosis of SARS-CoV-2 in special population, so as to provide reference for clinical research and differential diagnosis.

Key words: Coronavirus Genome structure Infection mechanism Epidemiology Clinical characteristics

收稿日期: 2020-05-07 出版日期: 2020-12-11

ZTFLH:

Q939.4

基金资助: * 中国工程院咨询项目(2020-KYGG-02-02);温州市新冠病毒肺炎疫情防控应急公关项目(ZY202002)

通讯作者: 黄志锋 E-mail: hzf@wmu.edu.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	程子昭
	陈楚楚
	应磊
	李校堃
	黄志锋

引用本文:

程子昭,陈楚楚,应磊,李校堃,黄志锋. 冠状病毒基因组特征及感染特点比较^*[J]. 中国生物工程杂志, 2020, 40(11): 56-66.

CHENG Zi-zhao,CHEN Chu-chu,YING Lei,LI Xiao-kun,HUANG Zhi-feng. Comparison of Genomic and Infection Characteristics of Coronavirus. China Biotechnology, 2020, 40(11): 56-66.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2005012 或 https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I11/56

表1 各种冠状病毒的基本信息

图1 可感染人类的7种冠状病毒的基因组示意图[14,15,16,17]

表2 各种冠状病毒及其对应的功能性受体

表3 各种冠状病毒的流行病学和临床表现特征

[1]	Worldometer. COVID-19 Coronavirus Pandemi. [2020-08-18]. https://www.worldometers.info/coronavirus/?from=singlemessage#countries.
[2]	Neuman B W, Adair B D, Yoshioka C, et al. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J Virol, 2006,80(16):7918-7928. doi: 10.1128/JVI.00645-06 pmid: 16873249
[3]	Hamre D, Procknow J J. A new virus isolated from the human respiratory tract. Proceedings of the Society for Experimental Biology & Medicine, 1966,121(1):190-193.
[4]	Pyrc K, Jebbink M F, Berkhout B, et al. Genome structure and transcriptional regulation of human coronavirus NL63. Virol J, 2004,1:7. pmid: 15548333
[5]	Van der Hoek L, Pyrc K, Berkhout B. Human coronavirus NL63, a new respiratory virus. FEMS Microbiology Reviews, 2006,30(5):760-773. doi: 10.1111/j.1574-6976.2006.00032.x pmid: 16911043
[6]	胡琴, 谭文杰. 人冠状病毒HCoV-OC43的研究进展. 中华预防医学杂志, 2013,47(7):661-664.
	Hu Q, Tan W J. Research progress of human coronavirus HCoV-OC43. Chinese Journal of Preventive Medicine, 2013,47(7):661-664.
[7]	Mcintosh K, Dees J H, Becker B W, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA, 1967,57(4):933-940. doi: 10.1073/pnas.57.4.933 pmid: 5231356
[8]	Woo P, Lau S, Yip C, et al. More and more coronaviruses: Human coronavirus HKU1. Viruses, 2009,1(1):57-71. doi: 10.3390/v1010057 pmid: 21994538
[9]	刘培林, 史蕾, 顾大勇, 等. 人冠状病毒HCoV-HKU1研究进展. 中国公共卫生, 2017,33(8):1264-1266.
	Liu P L, Shi L, Gu D Y, et al. Research progress of human coronavirus HCoV-HKU1. Chin J Publ Heal, 2017,33(8):1264-1266.
[10]	Rota P A, Oberste M S, Monroe S S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003,300(5624):1394-1399. pmid: 12730500
[11]	Weiss S R, Leibowitz J L. Coronavirus pathogenesis. Adv Virus Res, 2011,81:85-164. pmid: 22094080
[12]	Zaki A M, Boheemen S V, Bestebroer T M, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 2012,367(19):1814-1820. doi: 10.1056/NEJMoa1211721 pmid: 23075143
[13]	Chan J F, Kok K H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 2020,9(1):221-236. doi: 10.1080/22221751.2020.1719902 pmid: 31987001
[14]	Han Q, Lin Q, Jin S, et al. Coronavirus 2019-nCoV: A brief perspective from the front line. J Infect, 2020,80(4):373-377. doi: 10.1016/j.jinf.2020.02.010 pmid: 32109444
[15]	Oong X Y, Ng K T, Takebe Y, et al. Identification and evolutionary dynamics of two novel human coronavirus OC43 genotypes associated with acute respiratory infections: phylogenetic, spatiotemporal and transmission network analyses. Emerg Microbes Infect, 2017,6(1):e3. doi: 10.1038/emi.2016.132 pmid: 28050020
[16]	Pyrc K, Berkhout B, van der Hoek L. The novel human coronaviruses NL63 and HKU1. J Virol, 2007,81(7):3051-3057. doi: 10.1128/JVI.01466-06 pmid: 17079323
[17]	Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol, 2020,92(4):418-423. pmid: 31967327
[18]	Fehr A R, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol, 2015,1282:1-23. doi: 10.1007/978-1-4939-2438-7_1 pmid: 25720466
[19]	GISAID. GISAID EpiCoV Database.[2020-08-18]. https://db.cngb.org/gisaid/.
[20]	Lokman S M, Rasheduzzaman M, Salauddin A, et al. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. Infect Genet Evol, 2020,84:104389. doi: 10.1016/j.meegid.2020.104389 pmid: 32502733
[21]	Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Microbiology, 2020,7(6):1012-1023.
[22]	Korber B, Fischer W M, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell, 2020,18(4):812-827.
[23]	Tortorici M A, Walls A C, Lang Y, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol, 2019,26(6):481-489. pmid: 31160783
[24]	Li Z J, Tomlinson A C, Wong A H, et al. The human coronavirus HCoV-229E S-protein structure and receptor binding. [2020-08-18]. https://elifesciences.org/articles/51230
[25]	Vennema H, Godeke G J, Rossen W A J, et al. Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. The EMBO Journal, 1996,15(8):2020-2028. pmid: 8617249
[26]	Wilson L, McKinlay C, Gage P, et al. SARS coronavirus E protein forms cation-selective ion channels. Virology, 2004,330(1):322-331. pmid: 15527857
[27]	Yount B, Denison M R, Weiss S R, et al. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol, 2002,76(21):11065-11078. doi: 10.1128/jvi.76.21.11065-11078.2002 pmid: 12368349
[28]	Schelle B, Karl N, Ludewig B, et al. Selective replication of coronavirus genomes that express nucleocapsid protein. J Virol, 2005,79(11):6620-6630. doi: 10.1128/JVI.79.11.6620-6630.2005 pmid: 15890900
[29]	Wurm T, Chen H, Hodgson T, et al. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. J Virol, 2001,75(19):9345-9356.
[30]	Yeager C L, Ashmun R A, Williams R K, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature, 1992,357(6377):420-422. pmid: 1350662
[31]	Hofmann H, Pyrc K, van der Hoek L, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA, 2005,102(22):7988-7993. doi: 10.1073/pnas.0409465102 pmid: 15897467
[32]	Wu C. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue. [2020-8-18]. https://www.medrxiv.org/content/10.1101/2020.02.11.20022228v2.
[33]	Hulswit R J G, Lang Y, Bakkers M J G, et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc Natl Acad Sci USA, 2019,116(7):2681-2690.
[34]	Huang X, Dong W, Milewska A, et al. Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol, 2015,89(14):7202-7213. doi: 10.1128/JVI.00854-15 pmid: 25926653
[35]	Li W H, Moore M J, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003,426(6965):450-454. doi: 10.1038/nature02145 pmid: 14647384
[36]	Raj V S, Mou H H, Smits S L, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 2013,495(7440):251-254. pmid: 23486063
[37]	Lambeir A M, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crc Critical Reviews in Clinical Laboratory Sciences, 2003,40(3):209-294. doi: 10.1080/713609354 pmid: 12892317
[38]	Yeager C L, Ashmun R A, Williams R K, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature, 1992,357(6377):420-422. doi: 10.1038/357420a0 pmid: 1350662
[39]	Kawase M, Shirato K, Matsuyama S, et al. Protease-mediated entry via the endosome of human coronavirus 229E. J Virol, 2009,83(2):712-721. pmid: 18971274
[40]	Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol, 2013,87(11):6150-6160. doi: 10.1128/JVI.03372-12 pmid: 23536651
[41]	Milewska A, Zarebski M, Nowak P, et al. Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol, 2014,88(22):13221-13230. doi: 10.1128/JVI.02078-14 pmid: 25187545
[42]	Bakkers M J, Lang Y F, Feitsma L J, et al. Betacoronavirus adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity. Cell Host Microbe, 2017,21(3):356-366. pmid: 28279346
[43]	Vlasak R, Luytjes W, Spaan W, et al. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA, 1988,85(12):4526-4529. doi: 10.1073/pnas.85.12.4526 pmid: 3380803
[44]	Lim Y X, Ng Y L, Tam J P, et al. Human coronaviruses: A review of virus-host interactions. Diseases, 2016,4(3):26. doi: 10.3390/diseases4030026
[45]	Dominguez S R, Travanty E A, Qian Z H, et al. Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response. PLoS One, 2013,8(7):e70129. pmid: 23894604
[46]	Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 2005,436(7047):112-116.
[47]	Simmons G, Gosalia D N, Rennekamp A J, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA, 2005,102(33):11876-11881. pmid: 16081529
[48]	Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol, 2010,84(24):12658-12664.
[49]	Glowacka I, Bertram S, Muller M A, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol, 2011,85(9):4122-4134.
[50]	Zhu X J, Liu Q, Du L Y, et al. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis, 2013,5(Suppl 2):S142-148.
[51]	Lu G W, Hu Y W Wang Q H, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature, 2013,500(7461):227-231.
[52]	Hocke A C, Becher A, Knepper J, et al. Emerging human middle east respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. American Journal of Respiratory & Critical Care Medicine, 2013,188(7):882-886.
[53]	Doremalen N V, Miazgowicz K L, Milne-Price S, et al. Host species restriction of middle east respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol, 2014,88(16):9220-9232.
[54]	Barlan A, Zhao J C, Sarkar M K, et al. Receptor variation and susceptibility to middle east respiratory syndrome coronavirus infection. J Virol, 2014,88(9):4953-4961. pmid: 24554656
[55]	Xu X T, Chen P, Wang J F, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 2020,63(3):457-460.
[56]	Tai W B, He L, Zhang X J, Pu J, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol, 2020,17(6):613-620
[57]	Wong S H, Lui R N, Sung J J. Covid-19 and the digestive system. J Gastroenterol Hepatol, 2020,35(5):744-748. doi: 10.1111/jgh.15047 pmid: 32215956
[58]	Xu H, Zhong L, Deng J X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci, 2020,12(1):8. pmid: 32094336
[59]	Che X Y, Qiu L W, Liao Z Y, et al. Antigenic cross-reactivity between severe acute respiratory syndrome: associated coronavirus and human coronaviruses 229E and OC43. Journal of Infectious Diseases, 2005,191(12):2033-2037.
[60]	Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med, 2015,13:210.
[61]	Hunter J C, Nguyen D, Aden B, et al. Transmission of middle east respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi Emerg Infect Dis, 2016,22(4):647-656.
[62]	Anderson R M, Fraser C, Ghani A C, et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci, 2004,359(1447):1091-1105. doi: 10.1098/rstb.2004.1490 pmid: 15306395
[63]	de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 2016,14(8):523-534. doi: 10.1038/nrmicro.2016.81 pmid: 27344959
[64]	Leung G M, Hedley A J, Ho L M, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Annals of Internal Medicine, 2004,141(9):662-673.
[65]	Cowling B J, Park M, Fang V J, et al. Preliminary epidemiologic assessment of MERS-CoV outbreak in South Korea, May-June 2015. Euro Surveill, 2015,20(25):7-13.
[66]	Tsui P T, Kwok M L, Yuen H, et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerging Infectious Diseases, 2003,9(9):1064-1069.
[67]	Fisman D N. Hemophagocytic syndromes and infection. Emerging Infectious Diseases, 2000,6(6):601-608. doi: 10.3201/eid0606.000608 pmid: 11076718
[68]	Cheng V C C, Hung I F N, Tang B S F, et al. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. Clinical Infectious Diseases, 2004,38(4):467-475.
[69]	Puthucheary J, Lim D, Chan I, et al. Severe acute respiratory syndrome in Singapore. Archives of Disease in Childhood, 2004,89(6):551-556. pmid: 15155402
[70]	Ding Y Q, He L, Zhang Q L, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. The Journal of Pathology, 2004,203(2):622-630. doi: 10.1002/path.1560 pmid: 15141376
[71]	Peiris J S M, Lai S T, Poon L L M, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet, 2003,361(9366):1319-1325.
[72]	Leung C H, Gomersall C D. Middle east respiratory syndrome. Intensive Care Med, 2014,40(7):1015-1017.
[73]	Assiri A, Al-Tawfiq J A, Al-Rabeeah A A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious Diseases, 2013,13(9):752-761. pmid: 23891402
[74]	Chen N S, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020,395(10223):507-513.
[75]	房晓伟, 梅青, 杨田军, 等. 2019新型冠状病毒感染的肺炎79例临床特征及治疗分析. 中国药理学通报, 2020,36(4):1-7.
	Fang X W, Mei Q, Yang T J, et al. 2019 novel coronavirus pneumonia: clinical characteristics and treatment analysis of 79 cases. Chinese Pharmacological Bulletin, 2020,36(4):1-7.
[76]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020,395(10223):497-506.
[77]	Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr, 2020,87(4):281-286. doi: 10.1007/s12098-020-03263-6 pmid: 32166607
[78]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎防控方案(第六版).[2020-08-18]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml.
	National Health Commission of the People’s Republic of China. Novel coronavirus pneumonia prevention and control program (Sixth Edition). [2020-08-18]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml.
[79]	Gao Z, Xu Y, Sun C, et al. 新型冠状病毒肺炎防控方案(第六版).[2020-08-18]. https://www.sciencedirect.com/science/article/pii/S1684118220301134.
[80]	中华人民共和国国家卫生健康委员会. 关于新型冠状病毒无症状感染者的防控工作答问.[2020-08-18]. http://www.nhc.gov.cn/jkj/s3578/202003/718c79c96f3e46409dd49303d41a00ef.shtml.
	National Health Commission of the People’s Republic of China. Questions about novel coronavirus asymptomatic infection prevention and control.[2020-08-18]. http://www.nhc.gov.cn/jkj/s3578/202003/718c79c96f3e46409dd49303d41a00ef.shtml.
[81]	Li Q, Ding X, Xia G, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study. E Clinical Medicine. 2020,23:100375.
[82]	Pene F, Merlat A, Vabret A, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clinical Infectious Diseases, 2003,37(7):929-932. doi: 10.1086/377612 pmid: 13130404
[83]	Monto A S. Coronaviruses. The Yale Journal of Biology and Medicine, 1974,47(4):234-251.
[84]	Tyrrell D A J, Cohen S, Schilarb J E. Signs and symptoms in common colds. Epidemiol Infect, 1993,111(1):143-156. doi: 10.1017/s0950268800056764 pmid: 8394240
[85]	Abdul-Rasool S, Fielding B C. Understanding human coronavirus HCoV-NL63. The Open Virology Journal, 2010,4(1):76-84.
[86]	Woo P C Y, Lau S K P, Chu C M, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. Journal of Virology, 2004,79(2):884-895. pmid: 15613317
[87]	Gaunt E R, Hardie A, Claas E C J, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. Journal of Clinical Microbiology, 2010,48(8):2940-2947. doi: 10.1128/JCM.00636-10 pmid: 20554810
[88]	Fang F, Luo X P. Facing the pandemic of 2019 novel coronavirus infections the pediatric perspectives. Chin J Pediatr, 2020,58(2):81-85.
[89]	Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus disease in China. Pediatrics, 2020,58(4):712-713.
[90]	Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020,383(18):1708-1720. doi: 10.1056/NEJMp2016293 pmid: 32678529
[91]	Song W L, Li J H, Zou N, et al. Clinical features of pediatric patients with coronavirus disease (COVID-19). Journal of Clinical Virology, 2020,127:104377. doi: 10.1016/j.jcv.2020.104377 pmid: 32361323
[92]	Wu Z, McGoogan J M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020,323(13):1239-1242. doi: 10.1001/jama.2020.2648 pmid: 32091533
[93]	Zainab S, Ricci K, Brendan M, et al. COVID-19 and older adults: what we know. JAGS, 2020,68(5):926-929.
[94]	Wan Y, Shang J, Graham R, et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decadelong structural studies of SARS. J Virology, 2020, DOI: 10.1128/JVI.00127-20. doi: 10.1128/JVI.00127-20 pmid: 33239453
[95]	Li X C, Zhang J, Zhuo J L. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res, 2017,125(PtA):21-38.
[96]	Lei F, George K, Michael R. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection. The Lancet, 2020,8(4):e21. doi: 10.1016/S2213-2600(20)30116-8 pmid: 32171062
[97]	Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 criticallyill patients with COVID-19 in Washington State. JAMA, 2020,323(16):1612-1614. doi: 10.1001/jama.2020.4326 pmid: 32191259
[98]	Li B, Yang J, Zhao F M, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology, 2020,109(5):531-538. pmid: 32161990
[99]	Zhang L, Jiang Y, Wei M, et al. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province. Chin J Obstet Gynecol, 2020, DOI: 10.3760/cma.j.cn112141-20200218-00111/. doi: 10.3760/cma.j.cn112141-20200218-00111
[100]	Wendy N P, Olive P K. Is pregnancy a risk factor of COVID-19. EUR J OBSTET GYN R B, 2020,252:605-609.
[101]	Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 2005,11(8):875-879. doi: 10.1038/nm1267 pmid: 16007097
[102]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版).[2020-08-18]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
	National Health Commission of the People’s Republic of China. Diagnosis and treatment of novel coronavirus pneu- monia (trial version seventh).[2020-08-18]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.

[1]	贠涛,巩玥,谷芃,徐冰冰,李瑾,赵洗尘. 中国与“一带一路”参与国家抗击新冠肺炎疫情的国际科技合作现状与展望[J]. 中国生物工程杂志, 2021, 41(7): 110-121.
[2]	史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展^*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[3]	张赛,王刚,刘仲明,李辉军,汪大明,钱纯亘. 新型冠状病毒胶体金抗原快速检测试剂的研制及性能评价^*[J]. 中国生物工程杂志, 2021, 41(5): 27-34.
[4]	范月蕾,王跃,王恒哲,李丹丹,毛开云. 新型冠状病毒体外诊断技术研发现状与展望 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 150-161.
[5]	张赛,向乐,李林海,李辉军,王刚,钱纯亘. 新型冠状病毒(2019-nCoV)IgM /IgG抗体检测试剂的研制及性能评价[J]. 中国生物工程杂志, 2020, 40(8): 1-9.
[6]	谢华玲,吕璐成,杨艳萍. 全球冠状病毒疫苗专利分析[J]. 中国生物工程杂志, 2020, 40(1-2): 57-64.
[7]	巩玥,廖青云,于倩倩,史志祥,陈菁,张宇辉,赵光慧. 冠状病毒研究态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 21-37.
[8]	赵萍,杨艳萍. 人冠状病毒感染诊断技术专利态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 51-56.
[9]	李东巧,吕璐成,杨艳萍. 全球人冠状病毒抗体领域研发现状与发展趋势[J]. 中国生物工程杂志, 2020, 40(1-2): 65-70.
[10]	程永庆,刘金毅,林福玉,童梅. 重组人干扰素α1b与新型冠状病毒肺炎防治[J]. 中国生物工程杂志, 2020, 40(1-2): 71-77.
[11]	林福玉,刘金毅,程永庆. 重组人干扰素α1b抗新型冠状病毒的基础和临床研究进展[J]. 中国生物工程杂志, 2020, 40(12): 1-7.
[12]	王国强,于茵茵,曾华辉,王旭东,吴玉彬,尚立芝,李玉林,张怡青,张西西,张振强,王云龙. 基于MS2噬菌体病毒样颗粒的RT-PCR检测新型冠状病毒(SARS-CoV-2)质控品制备^*[J]. 中国生物工程杂志, 2020, 40(12): 31-40.
[13]	陈利军,屈晶晶,项春生. 间充质干细胞在2019新型冠状病毒肺炎(COVID-19)中的治疗潜能、临床研究与应用前景^*[J]. 中国生物工程杂志, 2020, 40(11): 43-55.
[14]	朱云鹏, 王鹏, 夏博然, 唐延婷, 王权. SARS冠状病毒主蛋白酶抑制剂的筛选及抑制动力学研究[J]. 中国生物工程杂志, 2016, 36(4): 35-42.
[15]	申梁, 谭文杰. 冠状病毒反向遗传操作技术及其应用进展[J]. 中国生物工程杂志, 2015, 35(2): 84-91.

Viewed

Full text

Abstract

Cited

Shared

Discussed